ProstaLund AB (PLUN) AI Stock Analysis

• Market Cap: kr1.33M
• Dividend Yield: N/A
• Average Volume (3M): 486.70K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.44
• Revenue Growth: -24.45%
• EPS Growth: 35.68%
• Country: SE
• Employees: 9
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -1.80
• Shares Outstanding: 3,624,052
• 10 Day Avg. Volume: 103,970
• 30 Day Avg. Volume: 486,699
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 43 Neutral
• Price Target: kr0.50 ▲(25.00% Upside)

ProstaLund AB's overall stock score is primarily impacted by its challenging financial performance and bearish technical indicators. The negative P/E ratio and lack of dividend yield further contribute to a low valuation score. The absence of earnings call data and corporate events leaves these areas unaddressed.

ProstaLund AB Business Overview & Revenue Model

Company Description

ProstaLund AB (PLUN) is a biotechnology company focused on developing innovative solutions for the treatment of prostate-related conditions, particularly benign prostatic hyperplasia (BPH). The company operates within the healthcare sector, specializing in medical devices and therapeutic solutions aimed at improving the quality of life for men experiencing urinary issues due to prostate enlargement. ProstaLund's core products include minimally invasive medical devices designed to alleviate symptoms associated with BPH, leveraging advanced technology to enhance patient outcomes and streamline surgical procedures.

How the Company Makes Money

ProstaLund AB generates revenue primarily through the sale of its medical devices and therapeutic solutions for prostate treatment. The company's revenue model is based on direct sales to hospitals and clinics, as well as partnerships with distributors in various markets. Key revenue streams include product sales, licensing agreements, and possibly royalties from any patented technologies. Significant partnerships with healthcare providers and research institutions further enhance its market reach and credibility, contributing to increased sales and potential funding for ongoing research and development initiatives.

ProstaLund AB Financial Statement Overview

Summary

ProstaLund AB faces significant profitability challenges with negative profit margins and returns. Despite a strong equity base and low leverage, persistent net losses and negative cash flow highlight ongoing operational struggles. Strategic improvements are needed to achieve sustainable growth.

Income Statement

ProstaLund AB has experienced declining revenues over the past years with a negative revenue growth rate from 2023 to TTM. The gross profit margin is relatively healthy at 65.9% for TTM, but the company is struggling with negative profitability, as indicated by a net profit margin of -164.0% and significant negative EBIT and EBITDA margins. The consistent net losses over the years highlight the company's struggle to reach profitability.

Balance Sheet

The company maintains a strong equity base with an equity ratio of 89.0% in TTM, indicating a solid financial stability. The debt-to-equity ratio is low at 0.02, reflecting minimal leverage. However, the return on equity is negative at -45.7%, driven by persistent net losses. Overall, the balance sheet remains stable with a strong equity position, but profitability challenges persist.

Cash Flow

ProstaLund AB's free cash flow remains negative and has shown a slight improvement in TTM with a reduction in negative free cash flow. The operating cash flow to net income ratio is above 1, indicating alignment between operating cash flow and net income, albeit both negative. The cash flow from financing activities continues to support liquidity, but the negative operating cash flow reflects ongoing operational challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	13.27M	13.72M	22.21M	17.41M	17.07M	12.46M
Gross Profit	8.72M	8.87M	15.65M	12.87M	14.68M	9.54M
EBITDA	-21.94M	-22.45M	-16.57M	-10.67M	-7.54M	-9.75M
Net Income	-22.23M	-22.63M	-17.01M	-11.30M	-7.92M	-10.04M
Balance Sheet
Total Assets	55.84M	61.64M	65.51M	51.04M	43.48M	30.84M
Cash, Cash Equivalents and Short-Term Investments	2.41M	7.82M	15.35M	12.28M	13.24M	10.49M
Total Debt	3.41M	933.00K	1.33M	1.73M	200.00K	600.00K
Total Liabilities	11.30M	6.46M	10.22M	9.36M	8.02M	5.49M
Stockholders Equity	44.54M	55.18M	55.29M	41.69M	35.46M	25.35M
Cash Flow
Free Cash Flow	-22.92M	-29.58M	-27.06M	-20.96M	-14.99M	-12.05M
Operating Cash Flow	-16.35M	-22.59M	-23.80M	-16.20M	-5.80M	-8.58M
Investing Cash Flow	-6.57M	-6.99M	-3.35M	-4.75M	-9.19M	-3.47M
Financing Cash Flow	21.95M	22.37M	30.22M	19.99M	17.73M	12.79M

ProstaLund AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PLUN, the sentiment is Negative. The current price of 0.4 is below the 20-day moving average (MA) of 0.74, below the 50-day MA of 0.79, and below the 200-day MA of 3.77, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 36.12 is Neutral, neither overbought nor oversold. The STOCH value of 5.30 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:PLUN.

ProstaLund AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BRAIN	50 Neutral	€201.70M	―	-26.66%	―	18.37%	34.23%
NXTCL	47 Neutral	kr101.92M	―	-89.24%	―	-15.28%	36.01%
CLS.B	43 Neutral	kr188.91M	―	-78.89%	―	57.14%	81.07%
PROGEN	43 Neutral	kr41.55M	―	-181.36%	―	-67.76%	95.76%
PLUN	43 Neutral	kr1.33M	―	-50.61%	―	-24.45%	35.68%
HEART	34 Underperform	kr136.46M	―	―	―	―	―